These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 10829251)

  • 21. Lipid and non-lipid effects of statins.
    Paoletti R; Bolego C; Cignarella A
    Handb Exp Pharmacol; 2005; (170):365-88. PubMed ID: 16596807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
    Mantell G
    Clin Exp Hypertens A; 1989; 11(5-6):927-41. PubMed ID: 2676263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin.
    Wierzbicki AS
    Expert Opin Pharmacother; 2001 May; 2(5):819-30. PubMed ID: 11336625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How do HMG-CoA reductase inhibitors prevent stroke?
    Bedi A; Flaker GC
    Am J Cardiovasc Drugs; 2002; 2(1):7-14. PubMed ID: 14727994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
    Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
    Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond the laboratory: clinical implications for statin pleiotropy.
    Halcox JP; Deanfield JE
    Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The promise of statins].
    Capurso A
    Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R; Lenzi S
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of statins on inflammation in patients with acute and chronic coronary syndromes.
    Kinlay S; Selwyn AP
    Am J Cardiol; 2003 Feb; 91(4A):9B-13B. PubMed ID: 12615293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.